\u79d1\u7814\u88fd\u85ac<\/a>\u2019IBD\u306e\u65b0\u305f\u306a\u6cbb\u7642\u9078\u629e\u80a2\u306e\u958b\u767a\u3092\u52a0\u901f\u3055\u305b\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u3066\u3001\u30a2\u30b8\u30a2\u306b\u304a\u3051\u308b\u7814\u7a76\u958b\u767a\u304a\u3088\u3073\u5546\u696d\u7684\u80fd\u529b\u3092\u6709\u3059\u308b\u300c\u30a8\u30fc\u30b6\u30a4\u682a\u5f0f\u4f1a\u793e\u300d\u3092\u8a2d\u7acb\u3057\u307e\u3057\u305f\u3002.<\/p>","protected":false},"excerpt":{"rendered":"Numab Therapeutics and Kaken Pharmaceutical have formed a partnership to develop NM81, a novel antibody that may become the first-ever treatment for inflammatory bowel disease. Kaken has entered into a licensing agreement for NM81 in some Asian territories following a research partnership beginning in November 2024. Under the new agreement, Numab and Kaken will jointly advance NM81 through clinical proof of concept. Kaken will fund both preclinical and clinical development. The agreement also includes financial terms tied to development. If products from this collaboration are successful, Kaken may receive payments from Numab reflecting its R&D investment in advancing NM81. Also Read: NEXT Oncology Partners with Kansai Medical University This partnership […]<\/p>\n","protected":false},"author":7,"featured_media":23979,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[208,181,89,211,237,206],"tags":[150,2550,9204,9205,9206],"ppma_author":[572],"class_list":{"0":"post-23978","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-apac","8":"category-biotech","9":"category-health-tech","10":"category-japan","11":"category-news","12":"category-regional","13":"tag-biotech","14":"tag-clinical-development","15":"tag-inflammatory-bowel-disease","16":"tag-kaken-pharmaceutical","17":"tag-numab-therapeutics"},"yoast_head":"\n
Numab & Kaken Team Up on NM81 for IBD Treatment<\/title>\n<meta name=\"description\" content=\"Numab and Kaken sign a strategic agreement to co-develop NM81, a novel multispecific antibody aimed at treating inflammatory bowel disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Numab & Kaken Team Up on NM81 for IBD Treatment\" \/>\n<meta property=\"og:description\" content=\"Numab and Kaken sign a strategic agreement to co-develop NM81, a novel multispecific antibody aimed at treating inflammatory bowel disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-14T12:16:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/Numab-Therapeutics-and-Kaken-Pharmaceutical-Announce-Licensing-and-Co-development-Agreement-for-Multispecific-Antibody-NM81-in-Inflammatory-Bowel-Disease-IBD.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30cc\u30de\u30d6\u3068\u79d1\u7814\u88fd\u85ac\u3001IBD\u6cbb\u7642\u85acNM81\u3067\u63d0\u643a","description":"\u30cc\u30de\u30d6\u3068\u79d1\u7814\u88fd\u85ac\u3001\u708e\u75c7\u6027\u8178\u75be\u60a3\u306e\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f\u591a\u7279\u7570\u6027\u6297\u4f53NM81\u306e\u5171\u540c\u958b\u767a\u306b\u95a2\u3059\u308b\u6226\u7565\u7684\u5951\u7d04\u3092\u7de0\u7d50.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/","og_locale":"ja_JP","og_type":"article","og_title":"Numab & Kaken Team Up on NM81 for IBD Treatment","og_description":"Numab and Kaken sign a strategic agreement to co-develop NM81, a novel multispecific antibody aimed at treating inflammatory bowel disease.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/","og_site_name":"itbusinesstoday","article_published_time":"2025-11-14T12:16:29+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/Numab-Therapeutics-and-Kaken-Pharmaceutical-Announce-Licensing-and-Co-development-Agreement-for-Multispecific-Antibody-NM81-in-Inflammatory-Bowel-Disease-IBD.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"1\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"Numab and Kaken Partner to Develop NM81 for IBD","datePublished":"2025-11-14T12:16:29+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/"},"wordCount":151,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/Numab-Therapeutics-and-Kaken-Pharmaceutical-Announce-Licensing-and-Co-development-Agreement-for-Multispecific-Antibody-NM81-in-Inflammatory-Bowel-Disease-IBD.webp","keywords":["Biotech","Clinical development","inflammatory bowel disease","Kaken Pharmaceutical","Numab Therapeutics"],"articleSection":["APAC","Biotech","Health Tech","Japan","News","Regional"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/","name":"\u30cc\u30de\u30d6\u3068\u79d1\u7814\u88fd\u85ac\u3001IBD\u6cbb\u7642\u85acNM81\u3067\u63d0\u643a","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/Numab-Therapeutics-and-Kaken-Pharmaceutical-Announce-Licensing-and-Co-development-Agreement-for-Multispecific-Antibody-NM81-in-Inflammatory-Bowel-Disease-IBD.webp","datePublished":"2025-11-14T12:16:29+00:00","description":"\u30cc\u30de\u30d6\u3068\u79d1\u7814\u88fd\u85ac\u3001\u708e\u75c7\u6027\u8178\u75be\u60a3\u306e\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f\u591a\u7279\u7570\u6027\u6297\u4f53NM81\u306e\u5171\u540c\u958b\u767a\u306b\u95a2\u3059\u308b\u6226\u7565\u7684\u5951\u7d04\u3092\u7de0\u7d50.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/Numab-Therapeutics-and-Kaken-Pharmaceutical-Announce-Licensing-and-Co-development-Agreement-for-Multispecific-Antibody-NM81-in-Inflammatory-Bowel-Disease-IBD.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/Numab-Therapeutics-and-Kaken-Pharmaceutical-Announce-Licensing-and-Co-development-Agreement-for-Multispecific-Antibody-NM81-in-Inflammatory-Bowel-Disease-IBD.webp","width":1200,"height":800,"caption":"Numab Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/numab-and-kaken-partner-to-develop-nm81-for-ibd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Numab and Kaken Partner to Develop NM81 for IBD"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/23978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=23978"}],"version-history":[{"count":3,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/23978\/revisions"}],"predecessor-version":[{"id":23991,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/23978\/revisions\/23991"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/23979"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=23978"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=23978"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=23978"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=23978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}